PTEN genetic alterations, primarily homozygous deletion, are common in advanced prostate cancer and significantly correlate with poor outcome and elevated PI3K-AKT-mTOR signaling [13,14,37,39,98,99]. This evidence concerns the gene PIK3CD and prostate cancer.